Cellular and animal models of cystic fibrosis, tools for drug discovery

Drug Discovery Today: Disease Models

Volumn 3, Issue 3, 2006, Pages 251-259

  Scholte, Bob J ^a   Colledge, William H ^b   Wilke, Martina ^a   de Jonge, Hugo ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; PHENYLGLYCINE; PHOSPHODIESTERASE INHIBITOR; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE; TETRAHYDROTHIOPHENE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CLINICAL FEATURE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG RESEARCH; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENE TARGETING; GENETIC CODE; GENETIC SUSCEPTIBILITY; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; HUMAN; IMMOBILIZED CELL; IN VITRO STUDY; LENTIVIRUS VECTOR; MUTATIONAL ANALYSIS; NONHUMAN; NONVIRAL GENE THERAPY; PATCH CLAMP; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

EID: 33751239440     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2006.09.003     Document Type: Review

References (46)

1. Gadsby D.C., et al. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440 (2006) 477-483
2. Riordan J.R. Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67 (2005) 701-718
3. Zhang H., et al. Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem. 281 (2006) 11312-11321
4. Swiatecka-Urban A., et al. The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. J. Biol. Chem. 280 (2005) 36762-36772
5. Guggino W.B., and Stanton B.A. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat. Rev. Mol. Cell Biol. 7 (2006) 426-436
6. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 67 (2000) 117-133
7. Rowntree R.K., and Harris A. The phenotypic consequences of CFTR mutations. Ann. Hum. Genet. 67 PT 5 (2003) 471-485
8. Davies J.C., et al. Modifier genes in cystic fibrosis. Pediatr. Pulmonol. 39 (2005) 383-391
9. Cutting G.R. Modifier genetics: cystic fibrosis. Annu. Rev. Genomics Hum. Genet. 6 (2005) 237-260
10. Bear C.E., et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68 (1992) 809-818
11. Nagel G., et al. CFTR fails to inhibit the epithelial sodium channel ENaC expressed in Xenopus laevis oocytes. J. Physiol. 564 Pt 3 (2005) 671-682
12. Jentsch T.J. Chloride channels: a molecular perspective. Curr. Opin. Neurobiol. 6 (1996) 303-310
13. Gruenert D.C., et al. Established cell lines used in cystic fibrosis research. J. Cyst. Fibros. 3 Suppl. 2 (2004) 191-196
14. Bals R., et al. Isolation and air-liquid interface culture of human large airway and bronchiolar epithelial cells. J. Cyst. Fibros. 3 S2 (2004) 49-51
15. Becker M.N., et al. Cytokine secretion by cystic fibrosis airway epithelial cells. Am. J. Respir. Crit. Care Med. 169 (2004) 645-653
16. Davidson D.J., et al. A primary culture model of differentiated murine tracheal epithelium [In Process Citation]. Am. J. Physiol. Lung Cell Mol. Physiol. 279 (2000) L766-L778
17. Grubb B.R., et al. Culture of murine nasal epithelia: model for cystic fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 290 (2006) L270-L277
18. Filali M., et al. Xenograft model of the CF airway. Methods Mol. Med. 70 (2002) 537-550
19. Grubb B.R. Ion transport across the normal and CF neonatal murine intestine. Am. J. Physiol. 277 1 Pt 1 (1999) G167-G174
20. De Jonge H.R., et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J. Cyst. Fibros. 3 Suppl. 2 (2004) 159-163
21. Veeze H.J., et al. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J. Clin. Invest. 93 (1994) 461-466
22. Davidson D.J., and Dorin J.R. The CF mouse: an important tool for studying cystic fibrosis. Expert Rev. Mol. Med. (2001). http://www-ermm.cbcu.cam.ac.uk/01002551h.htm (http://www-ermm.cbcu.cam.ac.uk/01002551h.htm)
23. Scholte B.J., et al. Animal models of cystic fibrosis. J. Cyst. Fibros. 3 Suppl. 2 (2004) 183-190
24. Grubb B.R., and Boucher R.C. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol. Rev. 79 Suppl. 1 (1999) S193-S214
25. Zhou L., et al. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266 (1994) 1705-1708
26. van Heeckeren A.M., et al. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am. J. Respir. Crit. Care Med. 173 (2006) 288-296
27. Cannon C.L., et al. Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator. Am. J. Respir. Cell Mol. Biol. 29 (2003) 188-197
28. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10 (2004) 487-493
29. Griesenbach U., et al. Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 13 (2006) 1061-1067
30. Davies J.C. Gene and cell therapy for cystic fibrosis. Paediatr. Respir. Rev. 7 Suppl. 1 (2006) S163-S165
31. Roomans G.M. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Am. J. Respir. Med. 2 (2003) 413-431
32. Wilschanski M., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349 (2003) 1433-1441
33. Pedemonte N., et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115 (2005) 2564-2571
34. Noel S., et al. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild-type, G551D and F508del CFTR chloride channels. J. Pharmacol. Exp. Ther. 319 (2006) 349-359
35. Van Goor F., et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell Mol. Physiol. 290 (2006) L1117-L1130
36. Zaman K., et al. S-nitrosylating agents, a novel class of compounds that increase CFTR expression and maturation in epithelial cells. Mol. Pharmacol. 70 (2006) 1435-1442
37. Gelman M.S., and Kopito R.R. Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. Methods Mol. Biol. 232 (2003) 27-37
38. Vij N., et al. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem. 281 (2006) 17369-17378
39. Cohen F.E., and Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 426 (2003) 905-909
40. Vandivier R.W., et al. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129 (2006) 1673-1682
41. Wilson J.W., and Robertson C.F. Angiogenesis in paediatric airway disease. Paediatr. Respir. Rev. 3 (2002) 219-229
42. Hoiby N., et al. Eradication of early Pseudomonas aeruginosa infection. J. Cyst. Fibros. 4 Suppl. 2 (2005) 49-54
43. Larson J.E., and Cohen J.C. Developmental paradigm for early features of cystic fibrosis. Pediatr. Pulmonol. 40 (2005) 371-377
44. Durie P.R., et al. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am. J. Pathol. 164 (2004) 1481-1493
45. Sheppard D.N., et al. The patch-clamp and planar lipid bilayer techniques: powerful and versatile tools to investigate the CFTR Cl- channel. J. Cyst. Fibros. 3 Suppl. 2 (2004) 101-108
46. Di A., et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8 9 (2006) 933-944